Hybrigenics Pharma

Hybrigenics is a French biopharmaceutical company focused on the discovery and development of small molecule drugs, particularly those targeting protein-protein interactions. The company's lead clinical asset, Inecalcitol, is a potent vitamin D receptor agonist that has been evaluated in Phase 2 clinical trials for the treatment of prostate cancer and acute myeloid leukemia. Hybrigenics utilized its proprietary ULTImate Y2H platform to build a pipeline of ubiquitin-specific protease inhibitors, including a notable program targeting USP7 in collaboration with Servier. In recent years, the company has undergone a strategic transformation, merging with the biotech assets of DMS Group to expand into adipose-derived stem cell therapies and medical devices. Hybrigenics is listed on the Euronext Growth market in Paris and continues to manage its legacy oncology portfolio alongside its newer regenerative medicine initiatives.